Novartis

Diversified pharma

NVS · NYSE · Switzerland

Share price · NVS

$155.21+0.66 (+0.43%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.8M (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NVS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Sep 2026-13.9%
  2. 1 Sep 2026+6.0%
  3. 21 Jul 2026+2.9%
  4. 1 Jul 2026-1.6%
  5. 11 Jun 2026+3.9%
  6. 8 Jun 2026-1.8%
  7. 1 Jun 2026-3.0%
  8. 6 May 2026+2.0%
  9. 11 Mar 2026-3.6%
  10. 14 Jan 2026+3.2%

Share of unusual movement by asset

For each asset, the share of NVS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
remibrutinib
events and moves
106%
Iptacopan (Fabhalta)
events and moves
116%
Afuresertib
events and moves
94%
Ribociclib
events and moves
102%
secukinumab (Cosentyx)
events and moves
91%
Atrasentan (Vanrafia)
events and moves
5shown from 8 days
Ruxolitinib (Jakafi) (Jakafi)
events and moves
5shown from 8 days
Inclisiran (Leqvio)
events and moves
3shown from 8 days
Ofatumumab
events and moves
3shown from 8 days
bimagrumab
events and moves
2shown from 8 days
MRT-6160
events and moves
2shown from 8 days
Sacubitril/valsartan (Entresto)
events and moves
1shown from 8 days
Lifonebart (VHB937)
events and moves
1shown from 8 days
Brolucizumab-Dbll
events and moves
1shown from 8 days
VAY736
events and moves
1shown from 8 days
Pelacarsen
events and moves
1shown from 8 days
Delpacibart etedesiran
events and moves
1shown from 8 days
Ganaplacide/lumefantrine
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—22%
Other company news (earnings, financing, releases naming no asset)—15%
Sessions with no dated event—45%

Assets

(89 total)
89Total Assets
32Approved
13Phase 3 / Filed
44Phase 1–2 / Early
66Diseases
Quick filter:
Showing 89 of 89 assets
Target & Modality
Approved
PI3K-alphaSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Atrasentan(Vanrafia)
Approved
Endothelin A receptorSmall molecule
IgA Nephropathy
Approved
IL-2 receptor alpha (IL2RA)Monoclonal antibody
Organ Transplant Rejection
Kidney Transplant Rejection Prophylaxis
Approved
VEGF-AAntibody fragment
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Approved
METSmall molecule
Non-Small Cell Lung Cancer
Approved
Sodium channelsSmall molecule
Epilepsy
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer
Approved
P-selectinMonoclonal antibody
Sickle Cell Disease
Approved
BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Small molecule
Non-Small Cell Lung CancerMelanomaGlioma
entacapone(Comtess)
Approved
COMTSmall molecule
Parkinson's Disease
Approved
CGRP receptorMonoclonal antibody
Migraine
Approved
Alpha-adrenergic receptor · Adenosine receptorSmall molecule
Migraine
Approved
mTOR kinase · mTOR (mTORC1) (inhibitor)Small molecule
EpilepsyBreast CancerRenal Cell Carcinoma
HR+/HER2- Metastatic Breast Cancer
Approved
Sphingosine 1-phosphate receptor (S1PR, specifically S1P1) · S1P receptor · Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Small molecule
Multiple Sclerosis
Inclisiran(Leqvio)
Approved
PCSK9RNA / oligonucleotide
Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia

Discontinued programmes (7)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(123 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
LuxdegalutamidePhase 2Metastatic Hormone-sensitive Prostate Cancer
Est. primary completion 2026-12-03 · NCT06991556 · CT.gov ↗
What to watch
Iptacopan · FabhaltaPhase 2Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Est. primary completion 2026-12-30 · NCT06388941 · CT.gov ↗
What to watch
2027 (39)
January 2027 (4)
Inclisiran · LeqvioPhase 3Acute Coronary Syndrome
Est. primary completion 2027-01-16 · NCT07102628 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 3Breast Cancer
Est. primary completion 2027-01-28 · NCT05038735 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 2Breast Neoplasms
Est. primary completion 2027-01-29 · NCT04544189 · CT.gov ↗
What to watch
Est. primary completion 2027-01-29 · NCT04817618 · CT.gov ↗
What to watch
February 2027 (8)
RibociclibPhase 2Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors …
Est. primary completion 2027-02-01 · NCT02934568 · CT.gov ↗
What to watch
Trametinib + RibociclibPhase 2Melanoma
Est. primary completion 2027-02-02 · NCT04417621 · CT.gov ↗
What to watch
Cipargamin + Ganaplacide/lumefantrinePhase 2Uncomplicated Plasmodium Falciparum Malaria
Est. primary completion 2027-02-04 · NCT07811908 · CT.gov ↗
What to watch
remibrutinibPhase 3Chronic Spontaneous Urticaria (CSU)
Est. primary completion 2027-02-22 · NCT06868212 · CT.gov ↗
What to watch
Ribociclib + Alpelisib (BYL719) + LetrozolePhase 1/2Breast Cancer
Est. primary completion 2027-02-26 · NCT01872260 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 2Advanced Breast Cancer
Est. primary completion 2027-02-26 · NCT04524000 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 3Advanced HER2+Breast Cancer
Est. primary completion 2027-02-26 · NCT04208178 · CT.gov ↗
What to watch
EverolimusPhase 3Tuberous Sclerosis Complex
Est. primary completion 2027-02-26 · NCT02962414 · CT.gov ↗
What to watch
March 2027 (2)
EDI048Phase 2Cryptosporidiosis
Est. primary completion 2027-03-23 · NCT07249463 · CT.gov ↗
What to watch
VAY736Phase 3Systemic Lupus Erythematosus
Est. primary completion 2027-03-26 · NCT05639114 · CT.gov ↗
What to watch
April 2027 (4)
VAY736Phase 3Systemic Lupus Erythematosus
Est. primary completion 2027-04-12 · NCT05624749 · CT.gov ↗
What to watch
ArumakimigPhase 2Still´s Disease
Est. primary completion 2027-04-22 · NCT07203001 · CT.gov ↗
What to watch
BW-20829Phase 2Lipoprotein Disorder
Est. primary completion 2027-04-26 · NCT07235046 · CT.gov ↗
What to watch
Iptacopan · FabhaltaPhase 3Generalized Myasthenia Gravis
Est. primary completion 2027-04-30 · NCT06517758 · CT.gov ↗
What to watch
May 2027 (4)
Inclisiran · LeqvioPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2027-05-10 · NCT05030428 · CT.gov ↗
What to watch
GIA632Phase 2Atopic Dermatitis
Est. primary completion 2027-05-17 · NCT07220577 · CT.gov ↗
What to watch
remibrutinibPhase 3Hidradenitis Suppurativa
Est. primary completion 2027-05-17 · NCT06799000 · CT.gov ↗
What to watch
LuxdegalutamidePhase 1/2Prostate Cancer Metastatic
Est. primary completion 2027-05-25 · NCT05067140 · CT.gov ↗
What to watch
June 2027 (3)
remibrutinibPhase 3Hidradenitis Suppurativa
Est. primary completion 2027-06-03 · NCT06840392 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 2PIK3CA-related Overgrowth Spectrum (PROS)
Est. primary completion 2027-06-22 · NCT04980833 · CT.gov ↗
What to watch
Rapcabtagene autoleucelPhase 1/2Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Est. primary completion 2027-06-30 · NCT03960840 · CT.gov ↗
What to watch
July 2027 (6)
LuxdegalutamidePhase 2Prostatic Cancer, Castration-Resistant
Est. primary completion 2027-07-16 · NCT07047118 · CT.gov ↗
What to watch
EYU688Phase 2Dengue
Est. primary completion 2027-07-22 · NCT06006559 · CT.gov ↗
What to watch
LXE408Phase 2Chagas Disease
Est. primary completion 2027-07-22 · NCT06632600 · CT.gov ↗
What to watch
GXV813Phase 2Schizophrenia
Est. primary completion 2027-07-29 · NCT07467993 · CT.gov ↗
What to watch
CapmatinibPhase 2Advanced Solid Tumors Which Are cMET-dependent
Est. primary completion 2027-07-30 · NCT03040973 · CT.gov ↗
What to watch
VAY736Phase 2Diffuse Cutaneous Systemic Sclerosis
Est. primary completion 2027-07-30 · NCT06470048 · CT.gov ↗
What to watch
August 2027 (2)
ZigakibartPhase 3IgA Nephropathy, Immunoglobulin A Nephropathy
Est. primary completion 2027-08-10 · NCT05852938 · CT.gov ↗
What to watch
remibrutinibPhase 2Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Est. primary completion 2027-08-23 · NCT06865651 · CT.gov ↗
What to watch
September 2027 (3)
PKN605Phase 2Atrial Fibrillation
Est. primary completion 2027-09-09 · NCT07217067 · CT.gov ↗
What to watch
VAY736Phase 3Lupus Nephritis
Est. primary completion 2027-09-21 · NCT05126277 · CT.gov ↗
What to watch
Ruxolitinib (Jakafi)Phase 2Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
Est. primary completion 2027-09-30 · NCT02955940 · CT.gov ↗
What to watch
October 2027 (1)
Iptacopan · FabhaltaPhase 3Paroxysmal Nocturnal Hemoglobinuria
Est. primary completion 2027-10-18 · NCT04747613 · CT.gov ↗
What to watch
November 2027 (1)
Iptacopan · FabhaltaPhase 2Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Est. primary completion 2027-11-27 · NCT06797518 · CT.gov ↗
What to watch
December 2027 (1)
remibrutinibPhase 2Papulopustular Rosacea
Est. primary completion 2027-12-07 · NCT07681271 · CT.gov ↗
What to watch
2028 (27)
February 2028 (4)
Est. primary completion 2028-02-01 · NCT05562466 · CT.gov ↗
What to watch
Inclisiran · Leqvio + PelacarsenPhase 3Atherosclerotic Cardiovascular Disease (ASCVD)
Est. primary completion 2028-02-03 · NCT06813911 · CT.gov ↗
What to watch
Rapcabtagene autoleucelPhase 2Lupus Erythematosus, Systemic, Lupus Nephritis
Est. primary completion 2028-02-14 · NCT06581198 · CT.gov ↗
What to watch
remibrutinibPhase 3Generalized Myasthenia Gravis
Est. primary completion 2028-02-25 · NCT06744920 · CT.gov ↗
What to watch
March 2028 (2)
Inclisiran · LeqvioPhase 3Familial Hypercholesterolemia - Homozygous
Est. primary completion 2028-03-21 · NCT06597006 · CT.gov ↗
What to watch
Inclisiran · LeqvioPhase 3Familial Hypercholesterolemia - Heterozygous
Est. primary completion 2028-03-21 · NCT06597019 · CT.gov ↗
What to watch
April 2028 (1)
Atrasentan · Vanrafia + ZigakibartPhase 3IgA Nephropathy, Immunoglobulin A Nephropathy
Est. primary completion 2028-04-14 · NCT04573478 · CT.gov ↗
What to watch
May 2028 (4)
ITU512Phase 1/2Sickle Cell Disease
Est. primary completion 2028-05-01 · NCT06546670 · CT.gov ↗
What to watch
secukinumab · CosentyxPhase 3Polymyalgia Rheumatica
Est. primary completion 2028-05-08 · NCT06331312 · CT.gov ↗
What to watch
remibrutinib + Omalizumab · XolairPhase 3Chronic Spontaneous Urticaria
Est. primary completion 2028-05-24 · NCT07816328 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 2/3Lymphatic Malformations
Est. primary completion 2028-05-31 · NCT05948943 · CT.gov ↗
What to watch
June 2028 (2)
GIA632Phase 2Non-segmental Vitiligo
Est. primary completion 2028-06-06 · NCT07431177 · CT.gov ↗
What to watch
225Ac-PSMA-617Phase 2/3Prostate Cancer
Est. primary completion 2028-06-27 · NCT06780670 · CT.gov ↗
What to watch
July 2028 (2)
AMO959Phase 1/2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-ba …
Est. primary completion 2028-07-10 · NCT07226986 · CT.gov ↗
What to watch
Iptacopan · FabhaltaPhase 3Atypical Hemolytic Uremic Syndrome
Est. primary completion 2028-07-21 · NCT05935215 · CT.gov ↗
What to watch
September 2028 (5)
Lifonebart (VHB937)Phase 2Alzheimer's Disease
Est. primary completion 2028-09-14 · NCT07094516 · CT.gov ↗
What to watch
Atrasentan · VanrafiaPhase 3IgA Nephropathy (IgAN)
Est. primary completion 2028-09-17 · NCT07850752 · CT.gov ↗
What to watch
Ribociclib + ECI830Phase 1/2Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Est. primary completion 2028-09-25 · NCT06726148 · CT.gov ↗
What to watch
225Ac-PSMA-617Phase 3Prostate Cancer
Est. primary completion 2028-09-29 · NCT06855277 · CT.gov ↗
What to watch
OfatumumabPhase 3Relapsing Multiple Sclerosis
Est. primary completion 2028-09-30 · NCT03650114 · CT.gov ↗
What to watch
October 2028 (1)
Iptacopan · FabhaltaPhase 3IC-MPGN
Est. primary completion 2028-10-27 · NCT05755386 · CT.gov ↗
What to watch
November 2028 (4)
Rapcabtagene autoleucelPhase 1/2Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Est. primary completion 2028-11-01 · NCT07048197 · CT.gov ↗
What to watch
GIA632Phase 2Cutaneous Lichen Planus
Est. primary completion 2028-11-22 · NCT07775924 · CT.gov ↗
What to watch
GHZ339Phase 2Atopic Dermatitis
Est. primary completion 2028-11-27 · NCT06947993 · CT.gov ↗
What to watch
Rapcabtagene autoleucelPhase 2Scleroderma, Diffuse
Est. primary completion 2028-11-30 · NCT06655896 · CT.gov ↗
What to watch
December 2028 (2)
MRT-6160Phase 2Moderate to Severe Psoriatic Arthritis
Est. primary completion 2028-12-13 · NCT07801495 · CT.gov ↗
What to watch
ArumakimigPhase 2VEXAS Syndrome
Est. primary completion 2028-12-26 · NCT07748624 · CT.gov ↗
What to watch
2029 (24)
January 2029 (2)
VAY736Phase 2Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Est. primary completion 2029-01-18 · NCT07421167 · CT.gov ↗
What to watch
Alpelisib (BYL719)Phase 2PIK3CA-related Overgrowth Spectrum (PROS)
Est. primary completion 2029-01-29 · NCT06997588 · CT.gov ↗
What to watch
February 2029 (2)
MRT-6160Phase 2Sjögren's Disease
Est. primary completion 2029-02-19 · NCT07737743 · CT.gov ↗
What to watch
remibrutinibPhase 3Chronic Pruritus of Unknown Origin
Est. primary completion 2029-02-26 · NCT07811869 · CT.gov ↗
What to watch
March 2029 (3)
Rapcabtagene autoleucelPhase 2Idiopathic Inflammatory Myopathies
Est. primary completion 2029-03-09 · NCT06665256 · CT.gov ↗
What to watch
NIO752Phase 2Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
Est. primary completion 2029-03-26 · NCT07868328 · CT.gov ↗
What to watch
remibrutinibPhase 3IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Est. primary completion 2029-03-30 · NCT07768371 · CT.gov ↗
What to watch
April 2029 (1)
Inclisiran · LeqvioPhase 3Primary Prevention of Atherosclerotic Cardiovascular Disease
Est. primary completion 2029-04-16 · NCT05739383 · CT.gov ↗
What to watch
May 2029 (1)
Midostaurin · RydaptPhase 2FLT3-mutated Acute Myeloid Leukemia
Est. primary completion 2029-05-18 · NCT03591510 · CT.gov ↗
What to watch
June 2029 (2)
Rapcabtagene autoleucelPhase 2ANCA Associated Vasculitis (AAV)
Est. primary completion 2029-06-07 · NCT06868290 · CT.gov ↗
What to watch
TrametinibPhase 1/2Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Est. primary completion 2029-06-11 · NCT07468071 · CT.gov ↗
What to watch
July 2029 (5)
bimagrumabPhase 2Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction, Heart Failure, Preserved Ejection Fraction
Est. primary completion 2029-07 · NCT07920887 · CT.gov ↗
What to watch
crizanlizumab-tmca (Adakveo)Phase 3Sickle Cell Disease
Est. primary completion 2029-07-02 · NCT06439082 · CT.gov ↗
What to watch
VotoplamPhase 2Huntington Disease
Est. primary completion 2029-07-16 · NCT06254482 · CT.gov ↗
What to watch
NIO752Phase 3Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Est. primary completion 2029-07-20 · NCT07498426 · CT.gov ↗
What to watch
remibrutinibPhase 3Relapsing Multiple Sclerosis
Est. primary completion 2029-07-25 · NCT06846281 · CT.gov ↗
What to watch
August 2029 (2)
VAY736Phase 3Sjögren´s Disease
Est. primary completion 2029-08-15 · NCT07621809 · CT.gov ↗
What to watch
FWY003Phase 2Geographic Atrophy Secondary to Age-related Macular Degeneration
Est. primary completion 2029-08-21 · NCT07441642 · CT.gov ↗
What to watch
September 2029 (1)
Ribociclib + LetrozolePhase 3Early Breast Cancer
Est. primary completion 2029-09-07 · NCT05827081 · CT.gov ↗
What to watch
October 2029 (1)
Rapcabtagene autoleucelPhase 1/2Generalized Myasthenia Gravis
Est. primary completion 2029-10-26 · NCT06704269 · CT.gov ↗
What to watch
November 2029 (1)
LuxdegalutamidePhase 1/2Progressive Metastatic Castrate Resistant Prostate Cancer
Est. primary completion 2029-11-09 · NCT07206056 · CT.gov ↗
What to watch
December 2029 (3)
MRT-6160Phase 2Moderate to Severe Psoriatic Arthritis
Est. primary completion 2029-12-12 · NCT07923773 · CT.gov ↗
What to watch
remibrutinibPhase 3Chronic Pruritus of Unknown Origin
Est. primary completion 2029-12-19 · NCT07700056 · CT.gov ↗
What to watch
Ruxolitinib (Jakafi)Phase 3Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Est. primary completion 2029-12-31 · NCT06401356 · CT.gov ↗
What to watch
2030 (13)
January 2030 (1)
PelacarsenPhase 3Cardiovascular Disease and Lipoprotein(a)
Est. primary completion 2030-01-09 · NCT07517263 · CT.gov ↗
What to watch
March 2030 (1)
PelacarsenPhase 2Aortic Stenosis
Est. primary completion 2030-03-12 · NCT05646381 · CT.gov ↗
What to watch
April 2030 (1)
VotoplamPhase 3Huntington Disease
Est. primary completion 2030-04-02 · NCT07326709 · CT.gov ↗
What to watch
May 2030 (1)
RibociclibPhase 3Early Breast Cancer
Est. primary completion 2030-05-29 · NCT03701334 · CT.gov ↗
What to watch
June 2030 (2)
Rapcabtagene autoleucelPhase 1/2Progressive Multiple Sclerosis
Est. primary completion 2030-06-14 · NCT06675864 · CT.gov ↗
What to watch
Iptacopan · FabhaltaPhase 3Primary Immunoglobulin A Nephropathy (IgAN)
Est. primary completion 2030-06-28 · NCT06994845 · CT.gov ↗
What to watch
July 2030 (1)
ZigakibartPhase 2Immunoglobulin A Nephropathy (IgAN)
Est. primary completion 2030-07-12 · NCT07146906 · CT.gov ↗
What to watch
August 2030 (1)
Rapcabtagene autoleucelPhase 1/2Relapsing Multiple Sclerosis
Est. primary completion 2030-08-07 · NCT06617793 · CT.gov ↗
What to watch
October 2030 (1)
PacibekitugPhase 3Myocardial Infarction
Est. primary completion 2030-10-22 · NCT07938411 · CT.gov ↗
What to watch
December 2030 (4)
remibrutinibPhase 3Secondary Progressive Multiple Sclerosis (SPMS)
Est. primary completion 2030-12-03 · NCT07225504 · CT.gov ↗
What to watch
Iptacopan · FabhaltaPhase 3Primary IgA Nephropathy
Est. primary completion 2030-12-04 · NCT04557462 · CT.gov ↗
What to watch
PelacarsenPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2030-12-08 · NCT06875973 · CT.gov ↗
What to watch
AbelacimabPhase 3Atrial Fibrillation (AF)
Est. primary completion 2030-12-30 · NCT07739888 · CT.gov ↗
What to watch
2031 (9)
January 2031 (1)
Ruxolitinib (Jakafi)Phase 3Graft-versus-host Disease (GVHD)
Est. primary completion 2031-01-17 · NCT06615050 · CT.gov ↗
What to watch
March 2031 (1)
DJI136Phase 1/2Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Est. primary completion 2031-03-03 · NCT07564401 · CT.gov ↗
What to watch
May 2031 (3)
QCZ484Phase 2Hypertension (HTN)
Est. primary completion 2031-05-07 · NCT07543120 · CT.gov ↗
What to watch
Letrozole + GVV858Phase 1/2Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2031-05-09 · NCT07288359 · CT.gov ↗
What to watch
DFT383Phase 1/2Nephropathic Cystinosis
Est. primary completion 2031-05-28 · NCT06910813 · CT.gov ↗
What to watch
June 2031 (1)
ZigakibartPhase 3Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA …
Est. primary completion 2031-06-25 · NCT06858319 · CT.gov ↗
What to watch
September 2031 (1)
Atrasentan · VanrafiaPhase 3Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Est. primary completion 2031-09-15 · NCT07498335 · CT.gov ↗
What to watch
October 2031 (2)
Iptacopan · FabhaltaPhase 3Paroxysmal Nocturnal Hemoglobinuria (PNH)
Est. primary completion 2031-10-14 · NCT06934967 · CT.gov ↗
What to watch
remibrutinibPhase 3Hidradenitis Suppurativa
Est. primary completion 2031-10-15 · NCT07665437 · CT.gov ↗
What to watch
2032 (3)
March 2032 (2)
Alpelisib (BYL719) + LetrozolePhase 2PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Est. primary completion 2032-03-23 · NCT07679269 · CT.gov ↗
What to watch
Inclisiran · LeqvioPhase 3Heterozygous or Homozygous Familial Hypercholesterolemia
Est. primary completion 2032-03-25 · NCT05682378 · CT.gov ↗
What to watch
July 2032 (1)
Iptacopan · FabhaltaPhase 3Atypical Hemolytic Uremic Syndrome
Est. primary completion 2032-07-16 · NCT05795140 · CT.gov ↗
What to watch
2033 (3)
January 2033 (1)
remibrutinibPhase 3Indication of the Parent Protocol
Est. primary completion 2033-01-30 · NCT07456891 · CT.gov ↗
What to watch
April 2033 (2)
VAY736Phase 2Primary Immune Thrombocytopenia (ITP)
Est. primary completion 2033-04-22 · NCT07660172 · CT.gov ↗
What to watch
VAY736Phase 3Sjogrens Syndrome
Est. primary completion 2033-04-22 · NCT05985915 · CT.gov ↗
What to watch
2034 (1)
April 2034 (1)
VAY736Phase 3Systemic Lupus Erythematosus
Est. primary completion 2034-04-03 · NCT06133972 · CT.gov ↗
What to watch
2035 (1)
August 2035 (1)
VAY736Phase 3Lupus Nephritis
Est. primary completion 2035-08-01 · NCT06711887 · CT.gov ↗
What to watch
2036 (1)
May 2036 (1)
Iptacopan · FabhaltaPhase 3C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Est. primary completion 2036-05-30 · NCT03955445 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(29)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalsecukinumabFDA approves Cosentyx in polymyalgia rheumatica
US, FDA · Source ↗
21 October 2026ApprovalsecukinumabEuropean Commission approves Cosentyx for polymyalgia rheumatica
EU, EC · Source ↗
October 2026ApprovalremibrutinibFDA approves Rhapsido for symptomatic dermographism
US, FDA · Novartis · Source ↗
October 2026Topline resultAQW051Phase III of VQW-765 in social anxiety disorder did not meet its primary endpoint
8 September 2026Topline resultDelpacibart etedesiranPhase III HARBOR misses primary endpoint of vHOT
4 September 2026Topline resultPelacarsenLp(a)HORIZON Phase III topline: primary endpoint not met
Novartis · Source ↗
1 September 2026Topline resultremibrutinibNovartis reports the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing MS met their primary endpoint
Novartis · Source ↗
25 August 2026Topline resultVHB937 (lifonebart)Phase 2 ASTRALS in ALS misses primary and secondary endpoints; ALS development discontinued
Novartis · Source ↗
11 August 2026Filing acceptedAfuresertib (GSK2110183)China NMPA accepts afuresertib NDA
CN, NMPA · Laekna · Source ↗
17 July 2026ApprovalIptacopanFDA grants traditional approval to Fabhalta in primary IgAN
US, FDA · Source ↗
2 June 2026Topline resultRuxolitinib (Jakafi)SENTRY Phase 3 topline results were mixed
7 May 2026Topline resultRuxolitinib (Jakafi)TRuE-AD4 24-week final data for Opzelura cream

The 12 most recent of 29 past events are shown.

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2—$2.7B$6.7B—$6.7B operating cash flowreport ↗

Novartis reported R&D spend of $2,727M, up 15.2% YoY, cash and equivalents of $6,656M, and net income of $4,024M for Q2 2025.

Figures only: this period's report disclosed no narrative text

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2—$2.4B$7.9B—$4.9B operating cash flowreport ↗
2023-Q2—$2.5B$10.9B—$3.6B operating cash flowreport ↗
2022-Q2—$2.5B$3.6B—$3.8B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$11.2B$11.4B+ $98M short-term inv.—$19.1B operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$10.0B$11.5B+ $1.9B short-term inv.—$17.6B operating cash flowreport ↗
2023-FY—$11.4B$13.4B+ $569M short-term inv.—$14.5B operating cash flowreport ↗
2022-FY—$10.0B$7.5B+ $11.1B short-term inv.—$14.2B operating cash flowreport ↗
2021-FY—$9.5B$12.4B+ $13.0B short-term inv.—$15.1B operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,565 reporting institutions held 143.8M shares ($21.1B, 7.6% of shares outstanding).

#InstitutionSharesValue
1Fisher Asset Management, LLC13,885,749$2.1B
2MORGAN STANLEY8,527,037$1.3B
3DIMENSIONAL FUND ADVISORS LP8,110,116$1.2B
4PRIMECAP MANAGEMENT CO/CA/7,567,354$1.2B
5Dodge & Cox6,967,383$1.1B
6GOLDMAN SACHS GROUP INC6,525,771$996.8M
7LOOMIS SAYLES & CO L P5,426,100$828.8M
8BANK OF AMERICA CORP /DE/4,962,794$758.1M
9FRANKLIN RESOURCES INC3,409,944$520.9M
10BlackRock, Inc.2,949,760$450.6M
11NORTHERN TRUST CORP2,786,228$425.6M
12GQG Partners LLC2,447,272$373.8M
13ENVESTNET ASSET MANAGEMENT INC2,311,384$353.1M
14JANUS HENDERSON GROUP PLC2,275,938$347.6M
15Cullen Capital Management, LLC2,037,962$311.3M